Eden vs Remedy Meds (2026): prices, structure, verdict

On tirzepatide, Remedy Meds↗ is cheaper: $399 versus $408 a month all-in — a $9 monthly gap, $108 across a year of maintenance dosing, and Remedy Meds's figure is dose-flat while Eden's structure is not.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Eden is cheaper: $198 versus $299 a month all-in — a $101 monthly gap, $1,212 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Eden: the record, condensed

Eden’s tirzepatide program bills $408 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The structure is tiered: the advertised entry point is $348, but the maintenance figure — the one a full year is actually billed at — is $408. That $60 gap between the ad and the anniversary is the single most important line in this record.

A required $99/month membership is part of the deal, and part of the figure above: $309 of medication plus $99 of platform equals the $408 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #16 of 17 verified programs, with the floor $193/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $41 a month. A year at this figure: $4,896 monthly-billed.

Start with the load-bearing figure: $198 a month, all-in, is what Eden charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Inside that $198 sits a mandatory $99-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $99, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #10 of 20 in the verified semaglutide index — $65/month above the floor (Oak Longevity, $133) — and sits $151 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,376.

Operationally at Eden: shipping included; commitment membership auto-renews; cancellation membership auto-renews until cancelled; pharmacy not publicly named — ask in writing before paying; states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Eden page · visit Eden ↗

Remedy Meds: the record, condensed

Remedy Meds’s tirzepatide program bills $399 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. The price is dose-flat: the standard titration ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

There is no membership line. $399 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #15 of 17 verified programs, with the floor $184/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $50 a month. A year at this figure: $4,788 monthly-billed.

Start with the load-bearing figure: $299 a month, all-in, is what Remedy Meds charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $299 is the whole subscription, which makes Remedy Meds unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #19 of 20 in the verified semaglutide index — $166/month above the floor (Oak Longevity, $133) — and sits $50 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Operationally at Remedy Meds: shipping included; commitment unknown; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Remedy Meds page · visit Remedy Meds ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: Remedy Meds at $399, Eden at $408 — a $9 monthly spread that compounds to $108 over a maintenance year and $216 over two.

Structure sharpens the gap: Remedy Meds’s figure is dose-flat (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill the same), while Eden’s is not — so Remedy Meds’s number is a ceiling and Eden’s advertised entry ($348) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Eden’s total includes a mandatory $99/month membership; Remedy Meds has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $198 (Eden) against $299 (Remedy Meds). $101 a month sounds survivable; $1,212 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $101 gap is exactly what it appears to be.

Eden’s total includes a mandatory $99/month membership; Remedy Meds has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

A way to feel the $9 monthly gap: over a year it funds 0.3 extra months at Remedy Meds’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $216, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Eden $408/mo month-to-month against Remedy Meds $399/mo month-to-month. The order holds: Remedy Meds leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Eden $1,224 monthly; Remedy Meds $1,197 monthly — best path favors Remedy Meds by $27. 6 months: Eden $2,448 monthly; Remedy Meds $2,394 monthly — best path favors Remedy Meds by $54. 12 months: Eden $4,896 monthly; Remedy Meds $4,788 monthly — best path favors Remedy Meds by $108. 24 months: Eden $9,792 monthly; Remedy Meds $9,576 monthly — best path favors Remedy Meds by $216.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Eden $594 vs Remedy Meds $897 — $303 to Eden. 6 mo: Eden $1,188 vs Remedy Meds $1,794 — $606 to Eden. 12 mo: Eden $2,376 vs Remedy Meds $3,588 — $1,212 to Eden. 24 mo: Eden $4,752 vs Remedy Meds $7,176 — $2,424 to Eden.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Eden publishes “most states”; Remedy Meds publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Eden — membership auto-renews; membership auto-renews until cancelled. Remedy Meds — unknown; not published.

Evidence: Eden source-verified (captured 2026-08-05); Remedy Meds third-party reported (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #16 and #15 of 17: between them lie 0 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #10 and #19 of 20: between them lie 8 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Eden and Remedy Meds

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Eden: membership auto-renews until cancelled; Remedy Meds: not published) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings